
Charles Burdet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9162609/publications.pdf Version: 2024-02-01



CHADLES RUDDET

#	Article	IF	CITATIONS
1	Modeling the bacterial dynamics in the gut microbiota following an antibioticâ€induced perturbation. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 906-918.	1.3	4
2	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. Lancet Infectious Diseases, The, 2022, 22, 764-765.	4.6	8
3	High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure. JAMA Internal Medicine, 2022, 182, 906.	2.6	69
4	Modeling the Effect of DAV132, a Novel Colonâ€Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 109, 1045-1054.	2.3	11
5	Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clinical Microbiology and Infection, 2021, 27, 789.e1-789.e5.	2.8	52
6	Discontinuing Î ² -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet, The, 2021, 397, 1195-1203.	6.3	82
7	Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units during the first wave of the epidemic in France. PLoS ONE, 2021, 16, e0250728.	1.1	22
8	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clinical Microbiology and Infection, 2021, 27, 1826-1837.	2.8	77
9	Heparin-induced Thrombocytopenia Diagnosis: A Retrospective Study Comparing Heparin-induced Platelet Activation Test to 14C-serotonin Release Assay. TH Open, 2021, 05, e507-e512.	0.7	5
10	Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia. JAMA Network Open, 2021, 4, e2129566.	2.8	10
11	A Phase 3 Randomized Controlled Trial (MICROCARE) to Evaluate the Efficacy of DAV132 in Preventing Clostridioides Difficile Infection in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome and Treated with Intensive Chemotherapy. Blood, 2021, 138, 4437-4437.	0.6	0
12	Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. Journal of Antimicrobial Chemotherapy, 2020, 75, 3611-3618.	1.3	7
13	Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening. Gut Microbes, 2020, 12, 1800897.	4.3	38
14	Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial). Journal of Antimicrobial Chemotherapy, 2020, 75, 1611-1617.	1.3	9
15	Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): Results of EVADER-1 a nation-wide pharmacoepidemiologic study Journal of Clinical Oncology, 2020, 38, 4106-4106.	0.8	1
16	Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	35
17	HIV Infection in North African Patients. AIDS Research and Human Retroviruses, 2019, 35, 628-633.	0.5	1
18	DAV131A Protects Hamsters from Lethal <i>Clostridioides difficile</i> Infection Induced by Fluoroquinolones. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	3

CHARLES BURDET

#	Article	IF	CITATIONS
19	Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	7
20	Prescribers' experience and opinions on antimicrobial stewardship programmes in hospitals: a French nationwide survey. Journal of Antimicrobial Chemotherapy, 2019, 74, 2451-2458.	1.3	12
21	Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	41
22	Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). Journal of Antimicrobial Chemotherapy, 2019, 74, 739-745.	1.3	67
23	Experiences and perspectives of implementing antimicrobial stewardship in five French hospitals: a qualitative study. International Journal of Antimicrobial Agents, 2018, 51, 829-835.	1.1	25
24	Protection of the Human Gut Microbiome From Antibiotics. Journal of Infectious Diseases, 2018, 217, 628-636.	1.9	124
25	Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clinical Microbiology and Infection, 2018, 24, 125-132.	2.8	41
26	Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage. Clinical Microbiology and Infection, 2018, 24, 3-5.	2.8	48
27	Efficacy of cloxacillin versus cefazolin for methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial. BMJ Open, 2018, 8, e023151.	0.8	14
28	Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?. International Journal of Antimicrobial Agents, 2018, 52, 762-770.	1.1	48
29	Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	18
30	Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	19
31	Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study. AIDS Research and Human Retroviruses, 2017, 33, 11-16.	0.5	4
32	18FDG-PET/CT: a useful tool for the management of patients in infectious diseases. Infectious Diseases, 2017, 49, 155-157.	1.4	1
33	Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS ONE, 2017, 12, e0180888.	1.1	55
34	Change in Bacterial Diversity of Fecal Microbiota Drives Mortality in a Hamster Model of Antibiotic-induced Clostridium difficile Colitis. Open Forum Infectious Diseases, 2017, 4, S382-S382.	0.4	1
35	Modelling helps understanding reduction of mortality provided by DAV131A in a hamster model of moxifloxacin-induced Clostridium difficile colitis. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
36	Prospective Cohort Study of the Relative Abundance of Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli in the Gut of Patients Admitted to Hospitals. Antimicrobial Agents and Chemotherapy, 2016, 60, 6941-6944.	1.4	8

CHARLES BURDET

#	Article	IF	CITATIONS
37	Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia. Critical Care, 2016, 20, 375.	2.5	113
38	Intestinal carriage of Extended Spectrum Beta-Lactamase producing E. coli in women with urinary tract infections, Cameroon. Journal of Infection in Developing Countries, 2016, 10, 1135-1139.	0.5	16
39	Predictors of return rate for an HIV-positive result in a French Voluntary Counseling and Testing centre. International Journal of STD and AIDS, 2015, 26, 33-36.	0.5	7
40	Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. Journal of Antimicrobial Chemotherapy, 2015, 70, 1487-1494.	1.3	21
41	Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. European Journal of Clinical Pharmacology, 2015, 71, 75-83.	0.8	34
42	Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses. Clinical Microbiology and Infection, 2014, 20, 01035-01041.	2.8	23
43	Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 2354-2360.	1.3	35
44	Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle. Journal of Antimicrobial Chemotherapy, 2014, 69, 761-768.	1.3	16
45	Population pharmacokinetics of imipenem in critically ill patients with suspected ventilatorâ€associated pneumonia and evaluation of dosage regimens. British Journal of Clinical Pharmacology, 2014, 78, 1022-1034.	1.1	34
46	Escherichia coli Bacteremia in Children. Pediatric Infectious Disease Journal, 2014, 33, 872-879.	1.1	28
47	Trends in Human Fecal Carriage of Extended-Spectrum β-Lactamases in the Community: Toward the Globalization of CTX-M. Clinical Microbiology Reviews, 2013, 26, 744-758.	5.7	543
48	Complexity of Escherichia coli bacteremia pathophysiology evidenced by comparison of isolates from blood and portal of entry within single patients. International Journal of Medical Microbiology, 2013, 303, 529-532.	1.5	8
49	Persistence of Yellow Fever Vaccine–Induced Antibodies After Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 2458-2461.	2.6	37